胚系DNA修复突变前列腺癌患者的标准治疗结局:国际回顾性分析
该国际回顾性观察研究纳入390例已知胚系DNA损伤修复基因突变(gDDRm)状态的转移性前列腺癌(mPC)患者,其中60例为gDDRm携带者。结果显示gDDRm阳性与阴性患者在多西他赛、阿比特龙/恩扎卢胺的缓解率与无进展生存上无显著差异,从去势抵抗起的中位总生存亦相似。
要点
- gDDRm阳性mPC患者接受多西他赛及新型内分泌治疗获益与总体人群相似。
- 从去势抵抗起中位总生存gDDRm阳性3.2年 vs 阴性3.0年,p=0.73。
- PARP抑制剂/铂类与gDDRm阳性交互作用的总生存校正HR为0.59(95%CI 0.28-1.25;p=0.17)。
核心结论
- mPC患者中gDDRm状态似乎不影响其从标准治疗中的获益,与总体人群相似。
- PARP抑制剂/铂类与gDDRm阳性的交互作用未达统计学显著,需前瞻性研究进一步验证。
研究设计与样本
- 回顾性、国际、观察性研究,共纳入390例已知gDDRm状态的mPC患者。
- 其中60例为gDDRm携带者(含37例gBRCA2m),330例未检出gDDRm。
- 372例来自Royal Marsden(英国)、Weill-Cornell(纽约)与University of Washington(华盛顿),另18例gBRCA1/2m携带者来自澳大利亚kConFab consortium。
- 采用含每队列随机截距的混合效应模型(Weibull分布)分析。
主要发现
- 74%与69%的患者分别接受多西他赛与阿比特龙/恩扎卢胺治疗,36%接受PARP抑制剂和/或铂类。
- 从去势抵抗起中位总生存gDDRm阳性3.2年 vs 阴性3.0年,p=0.73。
- 多西他赛中位无进展生存gDDRm阳性6.8个月 vs 阴性5.1个月,差异无统计学意义;缓解率分别为61%与54%。
- 一线阿比特龙/恩扎卢胺中位无进展生存两组均为8.3个月,缓解率分别为46%与56%。
- PARP抑制剂/铂类与gDDRm阳性交互作用的总生存校正HR为0.59(95%CI 0.28-1.25;p=0.17)。
关键数值与推荐
- gDDRm阳性定义:检出胚系DNA损伤修复基因突变,共60例,其中gBRCA2m 37例。
- 多西他赛缓解率gDDRm阳性61%、阴性54%;一线阿比特龙/恩扎卢胺缓解率阳性46%、阴性56%。
- PARP抑制剂/铂类交互作用总生存校正HR 0.59(95%CI 0.28-1.25;p=0.17)。
临床怎么用
- 对于gDDRm阳性的mPC患者,多西他赛及阿比特龙/恩扎卢胺等标准治疗可按常规使用。
- PARP抑制剂/铂类的获益尚待前瞻性研究明确,不宜仅凭gDDRm状态改变标准治疗选择。
局限性
- 研究为回顾性分析,存在回顾性研究固有的偏倚。
- 部分患者来自既往患病率研究队列,队列间差异通过混合效应模型校正。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Germline DNA damage repair gene mutation (gDDRm) is found in >10% of metastatic prostate cancer (mPC). Their prognostic and predictive impact relating to standard therapies is unclear. OBJECTIVE: To determine whether gDDRm status impacts benefit from established therapies in mPC. DESIGN, SETTING, AND PARTICIPANTS: This is a retrospective, international, observational study. Medical records were reviewed for 390 mPC patients with known gDDRm status. All 372 patients from Royal Marsden (UK), Weill-Cornell (NY), and University of Washington (WA) were previously included in a prevalence study (Pritchard, NEJM 2016); the remaining 18 were gBRCA1/2m carriers, from the kConFab consortium, Australia. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Response rate (RR), progression-free survival (PFS), and overall survival (OS) data were collected. To account for potential differences between cohorts, a mixed-effect model (Weibull distribution) with random intercept per cohort was used. RESULTS AND LIMITATIONS: The gDDRm status was known for all 390 patients (60 carriers of gDDRm [gDDRm+], including 37 gBRCA2m, and 330 cases not found to carry gDDRm [gDDRm-]); 74% and 69% were treated with docetaxel and abiraterone/enzalutamide, respectively, and 36% received PARP inhibitors (PARPi) and/or platinum. Median OS from castration resistance was similar among groups (3.2 vs 3.0 yr, p=0.73). Median docetaxel PFS for gDDRm+ (6.8 mo) was not significantly different from that for gDDRm- (5.1 mo), and RRs were similar (gDDRm+=61%; gDDRm-=54%). There were no significant differences in median PFS and RR on first-line abiraterone/enzalutamide (gDDRm+=8.3 mo, gDDRm-=8.3 mo; gDDRm+=46%, gDDRm-=56%). Interaction test for PARPi/platinum and gDDRm+ resulted in an OS adjusted hazard ratio of 0.59 (95% confidence interval 0.28-1.25; p=0.17). Results are limited by the retrospective nature of the analysis. CONCLUSIONS: mPC patients with gDDRm appeared to benefit from standard therapies similarly to the overall population; prospective studies are ongoing to investigate the impact of PARPi/platinum. PATIENT SUMMARY: Patients with inherited DNA repair mutations benefit from standard therapies similarly to other metastatic prostate cancer patients.
引用
- Mateo J, Cheng HH, Beltran H, et al. Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. Eur Urol. 2018. PMID: 29429804. doi:10.1016/j.eururo.2018.01.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。